Patent intelligence · WO
WO 2017179025
POLYPEPTIDES ÉPITOPIQUES D'ALLERGÈNES DE POLLEN D'AMBROISIE
POLYPEPTIDES ÉPITOPIQUES D'ALLERGÈNES DE POLLEN D'AMBROISIE
Patent details — WO 2017179025
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Oct 19, 2017
- Expiration
- Oct 14, 2037
- Applicant
- ALK-ABELLÓ AS [DK]
- CPC classes
- A61K 39/ 36 A I, A61K/3936
Quick answer
WO 2017179025 (POLYPEPTIDES ÉPITOPIQUES D'ALLERGÈNES DE POLLEN D'AMBROISIE) is held by ALK-ABELLÓ AS [DK]. Status: granted. Granted Oct 19, 2017. Expires Oct 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALK-ABELLÓ AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 36 A I, A61K/3936
More from ALK-ABELLÓ AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2024200854
ANTICORPS DE LIAISON AUX ALLERGÈNES APPROPRIÉS POUR TRAITER DES ALLERGIES AU POLLEN D'ARBRE
granted -
EP 4302751
ORALE DÜNNFILME MIT GERINGER WASSERAKTIVITÄT
granted -
EP 4302750
ORALE DÜNNFILME ENTHALTEND ADRENALIN
granted -
CA 3259886
DISPOSITIFS DE DÉPLACEMENT D'IGE-FCERI
granted -
WO 2023232958
INHIBITEURS DE LA KINASE DE BRUTON POUR LE TRAITEMENT D'UNE RÉACTION ALLERGIQUE SOUDAINE
granted -
CA 3255134
COMPOSITION D'ALLERGÈNE D'ARACHIDE
granted -
WO 2019224246
MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE
granted -
HK 1249412
PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF
granted
Frequently asked questions
What is US patent 2017179025?
WO 2017179025 (POLYPEPTIDES ÉPITOPIQUES D'ALLERGÈNES DE POLLEN D'AMBROISIE) is held by ALK-ABELLÓ AS [DK]. Status: granted. Granted Oct 19, 2017. Expires Oct 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2017179025?
ALK-ABELLÓ AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2017179025 expire?
Our index shows an expiration date of Oct 14, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.